# Frequently Asked Questions: Semaglutide Research Literature

> Semaglutide FAQ: 27 questions on mechanism, dosing, side effects, weight loss, cardiovascular outcomes, and the compounded semaglutide regulatory context — answered from primary sources.

The following questions on semaglutide are answered from the clinical trial record — STEP, SUSTAIN, SELECT, PIONEER, FLOW, and ESSENCE — with citations to primary sources. This is a research digest, not clinical guidance.

## Definition and Mechanism

**What is semaglutide?**
A glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for type 2 diabetes, chronic weight management in adults and adolescents aged 12 and older, and MASH (August 2025). Studied across more than 50,000 participants in the STEP, SUSTAIN, PIONEER, SELECT, FLOW, and ESSENCE trial programs [1, 5, 20]. All formulations are prescription-only.

**What is semaglutide and why is it being studied for weight loss?**
GLP-1 receptor agonism was first developed for type 2 diabetes. Weight-loss investigation followed when early diabetes trials recorded substantial body weight reductions — the mechanism being central hypothalamic appetite suppression via arcuate nucleus GLP-1 receptors [9]. Higher-dose formulations tested in the STEP program (2.4 mg weekly) produced 14.9-15.2% mean weight loss over 68-104 weeks [1, 2].

**How does semaglutide work?**
Binds and activates GLP-1 receptors, producing: glucose-dependent insulin secretion (beta cells), glucagon suppression (alpha cells), gastric emptying delay (vagal signaling), hypothalamic POMC/CART neuron activation (appetite suppression), NPY/AgRP neuron inhibition (hunger suppression), and pleiotropic cardiorenal anti-inflammatory effects via AMPK/SIRT1 [10].

**How does semaglutide suppress appetite?**
Centrally, semaglutide accesses hypothalamic arcuate nucleus via circumventricular organs, activating appetite-suppressing POMC/CART neurons and inhibiting hunger-driving NPY/AgRP neurons [9]. Peripherally, it slows gastric emptying and enhances satiety hormone release. The weight-loss mechanism is reduced food intake [9].

## Weight Loss and Duration

**Do you gain weight after stopping semaglutide?**
Yes, consistently. STEP 4 (n=803) showed mean weight regain of +6.9% by week 68 in those switched to placebo after a 20-week run-in — compared with continued weight loss of -7.9% in those maintained on the drug [3].

**Do I need to be on semaglutide for the rest of my life?**
Long-term trial data consistently show weight regain and reversal of cardiometabolic improvements within 12 months of discontinuation [2, 3, 5]. The published literature does not establish a duration after which discontinuation maintains benefit.

**Will semaglutide reduce belly fat?**
Trial data confirm preferential visceral fat reduction. DXA data from the STEP 1 substudy (n=140) showed visceral fat mass reduced 27.4% and total fat mass reduced 19.3% at week 68 with semaglutide 2.4 mg [11].

## Safety and Side Effects

**What is the downside of semaglutide?**
Most common are GI events (nausea, vomiting, diarrhea, constipation), reported by 40-74% of trial participants during dose escalation, mostly mild-to-moderate [12]. Serious but less common documented risks include pancreatitis (0.2% vs <0.1% with placebo), gallbladder disease, and the FDA black-box warning for thyroid C-cell tumors based on rodent data [12, 14]. Lean mass loss (~10% absolute) is a documented finding [11].

**What is the most serious side effect of semaglutide?**
Acute pancreatitis is a documented serious adverse event (0.2% vs <0.1% placebo in STEP trials) [12]. Thyroid C-cell tumors were observed in rodent studies at suprapharmacological doses, driving the FDA black-box warning — no confirmed human cases in any clinical trial population [14].

**When are the worst side effects of semaglutide?**
GI side effects in clinical trials were most frequent during the dose-escalation phase (weeks 1-20 in the STEP titration protocol) [12]. Incidence declined significantly once participants reached and maintained the 2.4 mg maintenance dose.

**Who cannot take semaglutide?**
Populations consistently excluded from semaglutide trials: personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, history of pancreatitis, and pregnancy [14].

**What not to mix with semaglutide?**
Semaglutide slows gastric emptying, which can delay Tmax of co-administered oral drugs [8]. Insulin and sulfonylurea co-administration increased hypoglycemia risk in trial subgroups and are the primary pharmacodynamic interaction noted [8].

**Can semaglutide cause hair loss?**
Alopecia was reported by approximately 3% of semaglutide-treated participants versus approximately 1% on placebo in STEP program trials [12]. Researchers characterize the pattern as telogen effluvium secondary to rapid caloric restriction — a physiologic stress response, not a direct drug pharmacology effect [24].

## Pharmacokinetics

**What is the half-life of semaglutide?**
Approximately 165-168 hours (approximately 7 days) across studied populations — achieved via C18 fatty-diacid albumin binding (>99% albumin-bound) that protects against DPP-4 degradation and renal filtration [8].

**How long does semaglutide stay in your system?**
Plasma half-life approximately 165-168 hours; full clearance approximately 5 weeks after the final dose [8]. Subcutaneous Tmax: 24-72 hours after injection.

**How do I reconstitute a compounded semaglutide vial?**
Research protocols describe adding bacteriostatic water to lyophilized semaglutide; typical research concentrations are 5 mg/mL (1 mL per 5 mg vial) or 5 mg/mL (2 mL per 10 mg vial) [13]. FDA removed semaglutide from the drug shortage list in February 2025, closing shortage-pathway compounding authorization after April-May 2025 [13].

## Access and Prescription

**How do I obtain a semaglutide prescription and what does the process involve?**
Real-world prescribing requires physician evaluation, documented diagnosis, contraindication screening, and titration monitoring per FDA-labeled protocols [14].

**Why won't my doctor prescribe semaglutide for weight loss?**
Trial eligibility required BMI ≥27 with weight-related comorbidity or ≥30 [1, 4]. Real-world prescribing decisions reflect contraindications, patient-specific clinical assessment, formulary access, and insurance coverage.

**Do you need a doctor's prescription to access GLP-1 medications like semaglutide?**
All FDA-approved semaglutide formulations are prescription-only medications in the United States [13].

**How common is it for telehealth companies to offer compounded semaglutide?**
Telehealth prescribing expanded significantly during the 2022-2024 shortage period. FDA removed semaglutide from the drug shortage list in February 2025; shortage-period compounding pathways closed April-May 2025 [13].

## Compounded Semaglutide

**What are the studied dosing protocols for semaglutide?**
Obesity: 0.25 mg/week → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg maintenance [1]. T2DM SC: 0.25 mg → 0.5 mg → up to 2.0 mg [22]. Oral T2DM: 3 mg → 7 mg → 14 mg daily [23].

## Emerging Research

**What is semaglutide used for beyond weight loss and diabetes?**
Active research areas: cardiovascular risk reduction (SELECT, 20% MACE reduction) [5], kidney disease (FLOW, 24% reduction in major kidney outcomes) [19], MASH liver disease (ESSENCE, FDA approval August 2025) [20], adolescent obesity (STEP TEENS) [21], and alcohol use disorder (first RCT with positive findings, 2025) [18].

**Can semaglutide be studied for alcohol use disorder?**
A 9-week RCT (n=48) found semaglutide titrated to 1.0 mg weekly significantly reduced alcohol self-administration and craving versus placebo [18].

**Is semaglutide effective for cardiovascular outcomes?**
SELECT (n=17,604): 20% relative risk reduction in MACE in adults with obesity and established cardiovascular disease without diabetes [5]. HR 0.80 (95% CI 0.72-0.90; p<0.001).

**How does semaglutide compare to other GLP-1 agonists?**
Semaglutide's C18 fatty-diacid albumin-binding modification achieves ~168-hour half-life versus ~13 hours for earlier GLP-1 agonists. In head-to-head trials, semaglutide 1.0 mg outperformed dulaglutide (SUSTAIN-7) and liraglutide 1.8 mg (SUSTAIN-10) for both HbA1c and weight reduction [8].

## References

[1] Wilding JPH et al. STEP 1. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2] Garvey WT et al. STEP 5. Nat Med. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556320/
[3] Rubino D et al. STEP 4. JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/
[4] Davies M et al. STEP 2. Lancet. 2021;397:971-984. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract
[5] Lincoff AM et al. SELECT. N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[6] Marso SP et al. SUSTAIN-6. N Engl J Med. 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
[7] Husain M et al. PIONEER 6. N Engl J Med. 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
[8] Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide. Drug Des Devel Ther. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11215664/
[9] Gabery S et al. Semaglutide lowers body weight via distributed neural pathways. JCI Insight. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7213778/
[10] Papakonstantinou I et al. Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11674233/
[11] Wilding JPH et al. STEP 1 DXA substudy. J Endocr Soc. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
[12] Wilding JPH et al. STEP 1 adverse events. N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[13] Foley & Lardner. FDA Removes Semaglutide from Drug Shortage List. 2025. https://www.foley.com/insights/publications/2025/02/glp-1-drugs-fda-removes-semaglutide-from-drug-shortage-list/
[14] Davies M et al. STEP 2 safety. Lancet. 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract
[18] Hendershot CS et al. Semaglutide in AUD. JAMA Psychiatry. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/
[19] Perkovic V et al. FLOW. N Engl J Med. 2024. https://www.nejm.org/doi/10.1056/NEJMoa2403347
[20] Sanyal AJ et al. ESSENCE. N Engl J Med. 2025. https://www.prnewswire.com/news-releases/essence-phase-3-trial-of-semaglutide-showed-significant-improvements-at-72-weeks-in-adults-with-mash-published-in-nejm-302443359.html
[21] Weghuber D et al. STEP TEENS. N Engl J Med. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2208601
[22] Rodbard HW et al. SUSTAIN FORTE. Lancet Diabetes Endocrinol. 2021. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00174-1/abstract
[23] Aroda VR et al. PIONEER 1. Diabetes Care. 2019. https://diabetesjournals.org/care/article/42/9/1724/36289/PIONEER-1-Randomized-Clinical-Trial-of-the
[24] Alopecia and Semaglutide. PMC11909624. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11909624/

---

Clinical trial record for one compound — semaglutide — read from the primary sources and indexed here. Not a prescriber, not a vendor.